Bond.az - RenovoRx (NASDAQ: RNXT) reported first quarter EPS of $-0.090, worse than the analyst estimate of $-0.080.
Revenue for the quarter came in at $560K versus the consensus estimate of $542.67K.
The stock price closed at $0.86. It is down 7.96% in the last 3 months and down 22.61% in the last 12 months.
RenovoRx saw 1 positive and 1 negative EPS revision in the last 90 days.
According to Bond.Pro, RenovoRx’s Financial Health score is 'fair performance'.












